Skip to content

Clinical study on the safety and efficacy of umbilical cord blood mononuclear cells (UCB-MNCs) infusion in the treatment of decompensated cirrhosis

Clinical study on the safety and efficacy of umbilical cord blood mononuclear cells (UCB-MNCs) infusion in the treatment of decompensated cirrhosis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200056267
Enrollment
Unknown
Registered
2022-02-03
Start date
2022-02-07
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Decompensated cirrhosis

Interventions

Study group:Umbilical cord blood mononuclear cells

Sponsors

The 3rd People's Hospital of Zhengzhou
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Child-Pugh score of liver cirrhosis B or C; 2. 18-75 years old, male or female; 3. No serious systemic infection; 4. A large number of ascites should be controlled below the medium level; 5. Have not received drug treatment such as glucocorticoids, cytotoxic drugs, etc. that have a greater impact on the immune system before seeing a doctor; 6. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with autoimmune diseases; 2. People with allergies; 3. Patients with liver cancer; 4. Patients with heart, lung, kidney, and other organ failure.

Design outcomes

Primary

MeasureTime frame
Child-Pugh Score;

Secondary

MeasureTime frame
improvement of patient's symptoms;PS score;Laboratory Metrics;CHILD score;

Countries

China

Contacts

Public ContactDan Zhao

The 3rd People's Hospital of Zhengzhou

zhaodanyuji@163.com+86 13503813896

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026